Literature DB >> 9184174

Dissociation of bone formation markers in bone metastasis of prostate cancer.

M Koizumi1, H Maeda, K Yoshimura, T Yamauchi, T Kawai, E Ogata.   

Abstract

To clarify the meaning and clinical value of bone formation markers in bone metastasis from prostate cancer, we investigated the bone formation markers carboxy-terminal propeptide of type I procollagen (PICP), bone-specific alkaline phosphatase (BA1-p) and osteocalcin, so-called bone gla protein (BGP) in 43 prostate cancer patients with and 46 patients without overt bone metastasis. Patients with bone metastasis were evaluated repeatedly by bone scan at intervals of 3-6 months. The expression patterns of bone formation markers in patients with progression of bone metastasis became dissociated; BA1-p and PICP were elevated in patients with progression of bone metastasis but BGP was not. Instead, BGP showed slight elevation in patients with improvement and complete remission of bone metastasis. PICP, BA1-p and BGP are all bone formation markers, but each marker appears in a different phase of bone formation: PICP appears in proliferation phase, BA1-p appears in matrix maturation phase and BGP appears in late bone formation phase. Our findings that BGP was not elevated in progression of bone metastasis and that it increased slightly with improvement and complete remission of bone metastasis may imply that the bone formation that occurs in blastic bone metastasis is different from normal bone formation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9184174      PMCID: PMC2223543          DOI: 10.1038/bjc.1997.273

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  17 in total

Review 1.  Biochemical markers of bone metabolism.

Authors:  L Risteli; J Risteli
Journal:  Ann Med       Date:  1993-08       Impact factor: 4.709

2.  Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements.

Authors:  W J Shih; B Wierzbinski; J Collins; S Magoun; I W Chen; U Y Ryo
Journal:  J Nucl Med       Date:  1990-09       Impact factor: 10.057

3.  Serum osteocalcin concentration in patients with prostatic cancer.

Authors:  G Francini; S Bigazzi; V Leone; C Gennari
Journal:  Am J Clin Oncol       Date:  1988       Impact factor: 2.339

Review 4.  Criteria for evaluating patient responses to treatment modalities for prostatic cancer.

Authors:  N H Slack; G P Murphy
Journal:  Urol Clin North Am       Date:  1984-05       Impact factor: 2.241

5.  Excessive mineralization with growth plate closure in rats on chronic warfarin treatment.

Authors:  P A Price; M K Williamson; T Haba; R B Dell; W S Jee
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

6.  In situ hybridization to show sequential expression of osteoblast gene markers during bone formation in vivo.

Authors:  H Zhou; P Choong; R McCarthy; S T Chou; T J Martin; K W Ng
Journal:  J Bone Miner Res       Date:  1994-09       Impact factor: 6.741

7.  Sclerotic bone metastasis: radiologic-pathologic correlation.

Authors:  J Aoki; I Yamamoto; M Hino; C Shigeno; N Kitamura; H Itoh; K Torizuka; T Itoh; M Furuta
Journal:  Radiology       Date:  1986-04       Impact factor: 11.105

8.  Weekly chemotherapy in advanced prostatic cancer.

Authors:  G Francini; R Petrioli; A Manganelli; M Cintorino; S Marsili; A Aquino; S Mondillo
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

9.  Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastasis.

Authors:  M Sano; K Kushida; M Takahashi; T Ohishi; K Kawana; M Okada; T Inoue
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640

10.  Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer.

Authors:  T Kylmälä; T L Tammela; L Risteli; J Risteli; M Kontturi; I Elomaa
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

View more
  5 in total

1.  Three-dimensional trabecular bone architecture of the lumbar spine in bone metastasis from prostate cancer: comparison with degenerative sclerosis.

Authors:  Tsutomu Tamada; Teruki Sone; Yoshimasa Jo; Shigeki Imai; Yasumasa Kajihara; Masao Fukunaga
Journal:  Skeletal Radiol       Date:  2004-11-16       Impact factor: 2.199

2.  Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions.

Authors:  Nanda K Thudi; Chelsea K Martin; Murali V P Nadella; Soledad A Fernandez; Jillian L Werbeck; Joseph J Pinzone; Thomas J Rosol
Journal:  Prostate       Date:  2008-07-01       Impact factor: 4.104

3.  Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer.

Authors:  A Aruga; M Koizumi; R Hotta; S Takahashi; E Ogata
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  Markers of bone turnover for the management of patients with bone metastases from prostate cancer.

Authors:  P Garnero; N Buchs; J Zekri; R Rizzoli; R E Coleman; P D Delmas
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

5.  The Usefulness of Bone Biomarkers for Monitoring Treatment Disease: A Comparative Study in Osteolytic and Osteosclerotic Bone Metastasis Models.

Authors:  Marta Martín-Fernández; Karmele Valencia; Carolina Zandueta; Cristina Ormazábal; Susana Martínez-Canarias; Fernando Lecanda; Concepción de la Piedra
Journal:  Transl Oncol       Date:  2017-02-16       Impact factor: 4.243

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.